ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1012

The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis

Khalid Almutairi1, Johannes Nossent1, David Preen1, Helen Keen1 and Charles Inderjeeth1, 1The University of Western Australia, Perth, Western Australia, Australia

Meeting: ACR Convergence 2020

Keywords: Administrative Data, Epidemiology, meta-analysis, population studies, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

To determine the global population prevalence of rheumatoid arthritis (RA) based on published studies and assess factors that influence RA prevalence estimates.

Methods:

Four electronic databases were searched (ProQuest, MEDLINE, Web of Science, and EMBASE) for publications that reporting prevalence estimates of RA from 1980 and 2019. A random-effect meta-analysis model was used to produce the pooled prevalence estimates. The potential between-study heterogeneity was identified using sensitivity analysis, sub-group and meta-regression analyses.

Results:

A total of 67 studies were included in the meta-analysis, containing 742,246 RA patients and 211,592,925 healthy controls. The global RA prevalence estimate was 0.46% (95% confidence interval (CI): 0.39-0.54; I2=99.9%) with a 95% prediction interval (0.06–1.27). The RA point-prevalence was 0.45% (95% CI: 0.38- 0.53%) between 1986 and 2014, while the pooled period-prevalence was 0.46% (95% CI: 0.36% and 0.57%) from 1955 to 2015. The highest RA pooled prevalence (0.69%; 95% CI: 0.47–0.95) was derived from linked data sources studies. Based on meta-regression, the factors that explain the studies’ heterogeneity of RA prevalence, including geographical location, the risk bias assessment of studies and sample size.

Conclusion:

The global prevalence of RA between 1980 and 2019 was 460 per 100,000 population, with variations due to geographical location and study methodology. Linked data are the preferred method to estimate RA population prevalence as they provide the best case-ascertainment.

Figure 1: Forest plot of the pooled global prevalence of Rheumatoid Arthritis (RA) based on prevalence methods.

Table 1: The 95% prediction intervals for future RA prevalence estimates of different sub-groups category.


Disclosure: K. Almutairi, None; J. Nossent, None; D. Preen, None; H. Keen, Pfizer Australia, 8, Abbvie Australia, 8; C. Inderjeeth, Novartis Australia, 8, Amgen, 5, 8, Kiniksa, 2, Paradigm, 2, BMS, 2.

To cite this abstract in AMA style:

Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-global-prevalence-of-rheumatoid-arthritis-a-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-global-prevalence-of-rheumatoid-arthritis-a-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology